Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 6/20 | 0.40 |
| ▸ | CNR1 | P21554 | 4/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25873835 | 1.00 | TLR2 (0.41) | TLR2ALDH1A1LMNAL3MBTL1CNR2 | |
| SCHEMBL25873822 | 0.98 | L3MBTL1 (0.41) | TLR2ALDH1A1LMNAL3MBTL1CNR2 | |
| SCHEMBL25869422 | 0.86 | PTPN1 (0.42) | TLR2ALDH1A1LMNAL3MBTL1CNR2 | |
| SCHEMBL25869429 | 0.86 | PTPN1 (0.42) | TLR2ALDH1A1LMNAL3MBTL1CNR2 | |
| SCHEMBL4555844 | 0.86 | ALDH1A1 (0.52) | TLR2ALDH1A1LMNACNR2CNR1 | |
| SCHEMBL13058720 | 0.86 | ALDH1A1 (0.52) | TLR2ALDH1A1LMNACNR2CNR1 | |
| SCHEMBL25869681 | 0.85 | LMNA (0.50) | TLR2ALDH1A1LMNARECQLMAPT | |
| SCHEMBL25869643 | 0.85 | LMNA (0.50) | TLR2ALDH1A1LMNARECQLMAPT | |
| SCHEMBL25873950 | 0.83 | TLR2 (0.41) | TLR2ALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL31647542 | 0.82 | MAPT (0.47) | TLR2ALDH1A1LMNACNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | CETP, NPC1, LCAT | TLR2 1063/4885ALDH1A1 4264/4885LMNA 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.